In partnership with
October 14, 2025
Built by a former cannabis regulator, Policy, Decoded is your daily map through the chaos of U.S. cannabis and hemp policy - what happened, why it matters, and who it benefits.
Today’s edition is sponsored by 1440 Media, the quick-read daily newsletter trusted by over 3 million readers who start smarter. Click through to support them - and if you’ve got story ideas, tips, or sponsorship leads, we’re all ears. This project grows stronger every time you share what matters.
Ohio’s emergency hemp ban took effect this week as lawsuits hit federal court, testing whether states can block federally legal products to protect cannabis licensees. Psychedelic research revealed an entirely new anti-inflammatory pathway that could reshape drug development, and Florida’s governor admitted legalization’s popularity even while opposing it.
⚖️ Ohio’s Hemp Ban Sparks Federal Suits
🧬 Psychedelics Shift Science
🗳️ DeSantis Admits Legalization’s Popularity
Think critically. Move first.
Receive Honest News Today
Join over 4 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news. From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost. Experience news without the noise; let 1440 help you make up your own mind. Sign up now and invite your friends and family to be part of the informed.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: Ohio's ban on intoxicating hemp products took effect Tuesday as two hemp companies filed federal lawsuits challenging the prohibition and retailers reported consumers stockpiling THC seltzers over the weekend. The 90-day temporary ban gives legislators until mid-January to craft permanent regulations while hemp businesses face immediate decisions about relocating inventory, shutting down operations, or waiting for legal clarity that may not arrive before their cash runs out. One lawsuit argues Ohio violated the Commerce Clause by blocking federally legal interstate hemp trade to protect licensed cannabis operators, while another claims the ban is unconstitutionally vague for failing to define prohibited products. Hemp manufacturers are shipping perishable beverage inventory to Michigan and Kentucky, destroying compliant products that were legal to produce last week, or warehousing stock hoping for court intervention before it expires. CBD retailers told the Ohio Capital Journal that distributors are pulling products and landlords are threatening lease terminations over potential legal exposure, while craft breweries that added THC seltzers to their taprooms are cutting revenue projections they'd built expansion plans around.
💡 Why It Matters: If either lawsuit succeeds, hemp companies in the dozen other states with similar bans gain tested legal strategies for challenging prohibitions that look more like economic protectionism than public safety policy. The Commerce Clause argument has force because hemp is explicitly legal under federal law and moves freely in interstate commerce, making state bans vulnerable to constitutional challenges that cannabis prohibitions never faced. Ohio carved out licensed cannabis operators from the ban, so identical THC products remain legal through different retail channels, which weakens the state's public safety rationale and strengthens claims this is market protection rather than consumer protection. The 90-day window creates decision-forcing conditions for hemp businesses: too long to survive without revenue if you're operating on normal retail margins, too short to meaningfully relocate operations or pivot to new markets before potentially different permanent rules emerge. Consumer behavior during the panic buying demonstrates hemp products had real market penetration beyond gas station novelties, with established customer bases treating hemp beverages as their preferred THC delivery method over dispensary alternatives.
🧠 THC Group Take: The legislature will likely attempt more nuanced permanent regulations during the 90-day window, but no operator should build their business plan around that assumption given how we got here through legislative inaction in the first place. More importantly, Ohio's geography makes an outright ban unworkable: Michigan allows hemp beverages, meaning Ohio residents will simply drive across state lines to purchase products legally rather than stop consuming them. The panic buying already demonstrated consumer demand that doesn't disappear because state borders changed the rules. A permanent ban doesn't solve Ohio's stated concerns about unregulated intoxicating products; it just ensures those products get purchased in Michigan dispensaries or through gray market channels where Ohio has zero oversight, no tax revenue, and no ability to enforce safety standards. The smarter approach would regulate hemp products similarly to licensed cannabis with testing requirements, serving size limits, and age-gated retail, converting existing operators into compliant businesses rather than pushing them across state lines or underground. Whether Ohio's legislature recognizes this during the 90-day window remains uncertain, but the border state reality means prohibition isn't actually an option regardless of what permanent rules emerge. Hemp businesses deciding whether to wait or relocate need to evaluate whether Ohio legislators understand their enforcement limitations or whether they'll pass a permanent ban and declare victory while Ohio consumers keep buying hemp products, just elsewhere.
Fast-moving headlines, flagged for what matters.
New research published in Cell found that psychedelics like LSD and psilocybin reduce inflammation through a mechanism completely separate from existing anti-inflammatory drugs, binding to the intracellular sigma-1 receptor rather than traditional surface receptors. The discovery matters because current anti-inflammatory treatments often lose effectiveness or cause serious side effects with long-term use, while psychedelics achieved comparable results through an entirely different biological pathway. University of Pittsburgh researchers tested the compounds on immune cells and found they suppressed inflammatory responses without requiring the drugs to cross the blood-brain barrier, opening potential applications for conditions like arthritis and cardiovascular disease where psychoactivity would be a barrier to treatment. The work gives pharmaceutical companies a new angle to pursue FDA approval for psychedelic compounds as non-psychoactive therapeutics, potentially accelerating regulatory acceptance by positioning these substances as novel anti-inflammatory agents rather than mental health treatments alone. Every state wrestling with psychedelic legalization frameworks should note that the therapeutic case just expanded beyond psychiatric applications into mainstream inflammation treatment, which changes the risk-benefit calculus regulators use to evaluate access policies. (Marijuana Moment)
California Department of Fish and Wildlife officials are warning that carbofuran, a pesticide banned in the US since 2009 due to extreme toxicity, is showing up widely on illegal cannabis cultivation sites across the Emerald Triangle. The chemical is so lethal that a quarter teaspoon can kill a 600-pound lion, and officials report finding it applied directly to cannabis plants and irrigation systems where it poisons wildlife, contaminates water sources, and persists in soil for years. Illegal growers are using carbofuran to protect crops from rodents and deer because it's cheap and available on the black market, despite criminal penalties that include fines up to $50,000 and a year in jail per violation. The widespread use undermines California's regulated market in a different way than usual: it's not just price competition from illegal grows but a public safety argument against all Emerald Triangle cannabis when contamination stories spread. Every state with legacy growing regions should recognize this as the endgame of prohibition economics, where cultivators priced out of legal markets don't just disappear but keep growing under conditions that create genuine environmental disasters regulators can't control. (KRCR News)
Florida Governor Ron DeSantis acknowledged that marijuana legalization polls well with voters even as he continues opposing Amendment 3, telling a conservative radio host that the measure has "some popularity" but claiming it would benefit big corporations over patients. DeSantis has spent months campaigning against the citizen initiative that needs 60% approval, holding press conferences with law enforcement and physicians to argue legalization would create public safety problems and enrich multi-state operators like Trulieve. The governor's admission that legalization is popular despite his opposition highlights the political bind Republicans face in purple states where cannabis support crosses party lines but the GOP base expects opposition. Trulieve has poured over $100 million into the campaign, making it the most expensive citizen initiative in Florida history and demonstrating how much MSOs will spend to crack the third-largest state population. If DeSantis can't kill a popular initiative despite his political capital and opposition infrastructure, it confirms that cannabis legalization has moved beyond partisan politics into basic voter preference territory that governors in other conservative states should note before picking similar fights. (Marijuana Moment)
New Hampshire lawmakers will consider adult-use cannabis legalization bills in the upcoming legislative session, continuing the state's annual pattern of debating legalization while remaining the only New England state without a legal market. The legislature has rejected legalization repeatedly despite being surrounded by legal states where Massachusetts, Maine, and Vermont dispensaries serve New Hampshire residents crossing borders to purchase legally. New Hampshire's hesitation gets more economically costly each year as tax revenue from its residents' cannabis purchases funds regulatory programs and municipal budgets in neighboring states instead of the Granite State. The political dynamics shift when you're the last holdout: legislators can't argue legalization is experimental or risky when it's working in every surrounding jurisdiction and your constituents are already consuming cannabis, just sending the tax dollars elsewhere. New Hampshire's position matters less as a political curiosity than as a case study in how border state economics eventually force legislatures to act, because when surrounding states capture all the revenue from your residents' consumption anyway, the policy question shifts from whether to legalize to how much longer you can afford not to. (Keene Sentinel)
Two Oklahoma medical marijuana patients filed a class-action lawsuit claiming the state's 7% excise tax is unconstitutional because the revenue no longer funds the regulatory program it was designed to support, demanding refunds for every patient who paid it since 2018. The lawsuit argues that once lawmakers redirected the excise tax from the Oklahoma Medical Marijuana Authority to general education and substance abuse programs, it violated Oklahoma's constitutional requirement that taxes "specify distinctly" their purpose. Plaintiffs claim patients are owed over $1 billion with interest, though actual collections total only $337 million, showing the mathematical sloppiness that often undermines these constitutional challenges. The legal theory has some merit: Oklahoma exempts medicine purchases from sales tax generally, so imposing a 7% excise specifically on medical marijuana for broad government purposes creates an equal protection argument. Fat chance this succeeds in Oklahoma courts though, where cannabis remains a Schedule I substance and judges aren't eager to order treasurers to refund $337 million for taxing a federally illegal drug that the state grudgingly tolerates under voter-approved medical programs. (Tulsa World)
A Missouri cannabis testing laboratory filed a lawsuit against a manufacturer for allegedly failing to pay $30,000 in testing fees, highlighting the cash flow pressures hitting service providers as cannabis companies stretch payment terms or simply don't pay. The lab claims it performed required compliance testing but the manufacturer stopped paying invoices, a pattern that's becoming more common as wholesale prices collapse and cultivators prioritize keeping lights on over paying vendors. Testing labs operate on thin margins because state regulations cap fees to keep costs down for licensees, so a few large unpaid invoices can threaten their viability even as demand for testing increases. The lawsuit matters less for the specific dollar amount than what it signals about financial stress spreading beyond cultivators and retailers into the infrastructure layer that makes legal markets function. Other state markets with payment term problems should watch whether Missouri labs start requiring prepayment or refusing service to financially shaky operators, because once testing capacity tightens due to lab closures, compliance bottlenecks can freeze entire supply chains. (St. Louis Post-Dispatch)
Arkansas regulators say they're in "no rush" to award the state's final two medical dispensary licenses despite a state Supreme Court ruling in August that invalidated the previous selection process and ordered new scoring. The Alcoholic Beverage Control Division is reviewing 14 applications under revised criteria but won't commit to a timeline, leaving applicants who've been waiting since 2022 in limbo while existing dispensaries continue operating without new competition. The delay comes as Arkansas voters prepare to decide on adult-use legalization in 2026, meaning regulators might be stalling until they know whether they're building out a medical program or converting to a much larger adult-use framework. Two licenses sounds trivial until you recognize that Arkansas capped dispensaries statewide, so these final permits are the last chance for new entrants before the market either stays frozen or explodes into adult-use. Every state with artificial license caps should watch how Arkansas handles this: regulators facing legal challenges on scoring can simply drag out compliance indefinitely, protecting incumbent operators from competition while claiming they're being careful about process. (Northwest Arkansas Democrat-Gazette)
States are writing wildly incompatible hemp-cannabis beverage regulations because no one agrees what problem they're solving, with Minnesota allowing 5mg THC per serving through regular retail while Oregon banned all intoxicating hemp products entirely. The real winner is beverage alcohol distributors who locked in THC access through existing three-tier systems in permissive states before regulators figured out what was happening. California's attempting a middle path with 0.3% THC hemp beverages alongside its adult-use system, creating two regulatory universes for functionally identical products. Companies that moved fast in Minnesota-style markets now have distribution infrastructure that later entrants can't replicate once states tighten rules. Federal abdication on hemp intoxicants means every state is building different frameworks, and the early movers in permissive jurisdictions just captured structural advantages that will compound as markets mature. (Brewbound)
Cannabis NB president Lori Stickles acknowledged that most New Brunswick residents still purchase from the illicit market despite legal sales being available since 2018, telling reporters the province hasn't made enough progress converting consumers to licensed retailers. The admission is remarkable because government cannabis executives rarely state the obvious this bluntly: six years after legalization, the legal market in Canada's third-smallest province still can't compete with illicit pricing and convenience. Stickles blamed high taxes and regulatory costs that keep legal prices above illicit alternatives, but didn't mention that Cannabis NB operates as a government monopoly that eliminated private retail competition and created the exact bureaucratic inefficiency that prevents illicit operators from migrating into licensed channels. New Brunswick's failure demonstrates what happens when governments design legal markets primarily to generate tax revenue rather than create pathways for legacy operators to join the regulated system: you end up with both an expensive legal structure AND a persistent illicit market running parallel indefinitely. If Canada can't make this work after six years with federal legalization, no state borders to manage, and banking access solved, US markets should recognize the problem isn't implementation timeline but fundamental design choices that price out both consumers and the legacy operators who actually know how to serve them profitably. (TJ.news (New Brunswick))
The Australian Medical Association and Pharmacy Guild are raising alarms about patient harm as medicinal cannabis prescriptions surged from 100,000 in 2021 to 300,000 in 2024, with doctors reporting they can't keep up with monitoring drug interactions and side effects from patients authorized through online prescription services. Physicians say telehealth platforms are flooding the market with cannabis approvals while traditional prescribers struggle to provide proper follow-up care, creating a system where patients get authorized but not adequately supervised for complications like blood thinner interactions. If you're running telehealth cannabis consultations in US medical states, this is your warning shot: prioritize actual patient relationships over prescription volume now, because when doctors start documenting adverse events from unsupervised use, regulators will crack down on the entire telehealth channel rather than distinguishing between responsible and irresponsible operators. Australia's experience follows a predictable pattern where rapid access expansion without clinical infrastructure eventually gives medical establishments the safety data they need to roll back programs. US medical cannabis companies should recognize that building genuine patient monitoring systems today is cheaper than defending your business model in legislative hearings after someone gets hurt. (The Nightly (Australia))
From the hearing room to the comment section — we’re watching it all.
💰 Curaleaf secured a $100 million credit facility at 11.5% interest, which sounds expensive until you remember most cannabis operators can't access institutional debt at any price. The deal came from a real estate finance firm that structured around property collateral rather than plant-touching assets, showing that sophisticated lenders are figuring out how to enter the sector without waiting for federal reform if operators have enough real estate to backstop the risk. (TipRanks)
🏭 OSHA's closure during the government shutdown means cannabis cultivation and alcohol production facilities are operating without federal workplace safety inspections, even though both industries involve significant chemical exposure and equipment hazards. The agency that's supposed to oversee everything from pesticide handling to CO2 extraction safety is simply gone until Congress figures out appropriations. Federal paralysis hits hardest in industries that can't rely on state regulators to fill the gap because most state cannabis agencies are already underwater on compliance monitoring. (The Fresh Toast)
🍺 The New York Times just ran a piece arguing that craft beer's decline stems partly from trying too hard to be weird, with overcomplicated names and gimmicky flavors alienating casual drinkers who just want something approachable. Hemp beverage companies launching with names like "Chill Vibes Mango Blast" or leaning into stoner aesthetics should pay attention: the lesson from craft beer is that novelty wears off fast, and sustainable consumer brands win by being something people aren't embarrassed to order in public. (The New York Times)